FDA Cites Manufacturing Issues for Cytisinicline - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Cites Manufacturing Issues for Cytisinicline

Application supported by Phase 3 smoking-cessation data and long-term safety findings.

  • By

  • Kathryn Wighton

  • June 22, 2026

  • 3 min

Share

  • 1

    The FDA issued a Complete Response Letter for cytisinicline, citing manufacturing issues at a third-party facility and incomplete product labeling.

  • 2

    No deficiencies related to the clinical efficacy or safety of cytisinicline were identified by the FDA.

  • 3

    Achieve Life Sciences plans to resubmit the New Drug Application in the fourth quarter of 2026, reflecting a new manufacturing partnership.

  • 4

    Cytisinicline has shown greater smoking abstinence rates in Phase 3 trials compared to placebo, with significant safety data from over 400 participants.

  • 5

    Achieve Life Sciences is developing cytisinicline for smoking cessation and has received FDA Breakthrough Therapy designation for e-cigarette cessation.

Original Source(s)

FDA Cites Manufacturing Issues for Cytisinicline

  • by Kathryn Wighton

  • June 22, 2026

Related Content

AI-Assisted MRI Method May Rival CT in Lung Nodule Detection

A rapid AI‐assisted imaging protocol detected nearly all clinically relevant solid lung nodules while closely matching CT for suspicious screening classifications.

AI diagnostics and what clinicians can verify in oncology

"The more AI changes what we do … the less able we are to check it.”

Medical debt linked to higher late-stage cancer rates

Lung cancer showed the strongest absolute association, while prostate and breast cancer findings diverged from the broader pattern.